What are Kardigan’s plans for its $320 million IPO funding?

Kardigan, a Bay Area biotech, aims to raise about $320 million through a Nasdaq IPO to advance three cardiovascular programs. It plans to allocate roughly $80–90 million each to danicamtiv and ataciguat, $40–50 million to tonlamarsen, and $50–60 million for broader R&D, continuing the MyoKardia legacy in heart disease innovation.